Acute renal failure in the newborn is a common problem and is typically classified as
prerenal, intrinsic renal disease including vascular insults, and obstructive uropathy. In the …

Background. Disturbances of calcium‐phosphate (Ca‐P) metabolism in chronic renal
insufficiency (CRI) play an important role not only in bone disease (renal osteodystrophy) …

Antacids used to decrease phosphorus absorption in patients with renal failure may be toxic.
To find more efficient or less toxic binders, a three-part study was conducted. First …

Calcium acetate, an effective phosphorus binder in patients with renal failure. Calcium salts
are increasingly used as phosphorus binders in patients with chronic renal failure. Calcium …

Childhood and adolescence are crucial times for the development of a healthy skeletal and
cardiovascular system. Disordered mineral and bone metabolism accompany chronic …

New advances in the pathogenesis of renal osteodystrophy (ROD) change the perspective
from which many of its features and treatment are viewed. Calcium, phosphate, parathyroid …

Chronic aluminium exposure and toxicity related to aluminium absorption and contaminated
dialysis fluid continue to be a problem for many patients with renal failure, particularly in …

Renal bone disease has been well defined in adult patients receiving chronic dialysis and in
children on peritoneal dialysis/continuous ambulatory peritoneal dialysis. However, little is …

Fourteen of 39 dialysis patients (36%) became hypercalcemic after switching to calcium
carbonate as their principal phosphate binder. In order to identify risk factors associated with …

Aluminium-or calcium-based phosphate-binding agents traditionally have been used to treat
hyperphosphataemia in patients with end-stage renal disease. Although these agents …